Literature DB >> 21947261

[Recurrence prevention of kidney stone disease].

M Straub1.   

Abstract

In each urolithiasis patient the individual risk for recurrence determines the need for specific medical treatment. Therefore, a brief evaluation of the risk status after stone passage is mandatory to define patients at high risk for recurrence. Only one quarter of all urolithiasis patients are at high risk or suffer from severe metabolic disorders, which both demand further metabolic work-up prior to medical therapy. However, the other three quarters benefit sufficiently from general preventive measures, such as high fluid intake, well-balanced mixed diet and lifestyle changes. This article summarizes the recent recommendations for stone-specific recurrence prevention, discusses the different pharmacological treatment options and sketches the follow-up concept for high risk patients with ongoing medication.

Entities:  

Mesh:

Year:  2011        PMID: 21947261     DOI: 10.1007/s00120-011-2640-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  25 in total

1.  Surgery for primary hyperparathyroidism.

Authors:  Henrik Ancher Sørensen
Journal:  BMJ       Date:  2002-10-12

Review 2.  Developments in stone prevention.

Authors:  Michael Straub; Richard E Hautmann
Journal:  Curr Opin Urol       Date:  2005-03       Impact factor: 2.309

3.  Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria.

Authors:  Loris Borghi; Tania Schianchi; Tiziana Meschi; Angela Guerra; Franca Allegri; Umberto Maggiore; Almerico Novarini
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

4.  Beverage use and risk for kidney stones in women.

Authors:  G C Curhan; W C Willett; F E Speizer; M J Stampfer
Journal:  Ann Intern Med       Date:  1998-04-01       Impact factor: 25.391

Review 5.  Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline.

Authors:  M Straub; W L Strohmaier; W Berg; B Beck; B Hoppe; N Laube; S Lahme; M Schmidt; A Hesse; K U Koehrmann
Journal:  World J Urol       Date:  2005-11-29       Impact factor: 4.226

6.  Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis.

Authors:  M S Pearle; C G Roehrborn; C Y Pak
Journal:  J Endourol       Date:  1999-11       Impact factor: 2.942

7.  Randomized trial of allopurinol in the prevention of calcium oxalate calculi.

Authors:  B Ettinger; A Tang; J T Citron; B Livermore; T Williams
Journal:  N Engl J Med       Date:  1986-11-27       Impact factor: 91.245

8.  Investigations of the efficacy of ascorbic acid therapy in cystinuria.

Authors:  H Birwé; W Schneeberger; A Hesse
Journal:  Urol Res       Date:  1991

Review 9.  Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials.

Authors:  Howard A Fink; Joseph W Akornor; Pranav S Garimella; Rod MacDonald; Andrea Cutting; Indulis R Rutks; Manoj Monga; Timothy J Wilt
Journal:  Eur Urol       Date:  2009-03-13       Impact factor: 20.096

10.  Dependence of oxalate absorption on the daily calcium intake.

Authors:  Gerd E von Unruh; Susanne Voss; Tilman Sauerbruch; Albrecht Hesse
Journal:  J Am Soc Nephrol       Date:  2004-06       Impact factor: 10.121

View more
  2 in total

Review 1.  Urolithiasis--an interdisciplinary diagnostic, therapeutic and secondary preventive challenge.

Authors:  Christian Fisang; Ralf Anding; Stefan C Müller; Stefan Latz; Norbert Laube
Journal:  Dtsch Arztebl Int       Date:  2015-02-06       Impact factor: 5.594

2.  An empirical study on hospital-based prevention of recurrent urinary stone disease in Germany.

Authors:  Alina Reicherz; Patricia Rausch; Roman Herout; Joachim Noldus; Peter Bach
Journal:  World J Urol       Date:  2021-08-18       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.